Real World Superiority Data May Not Be Enough To Boost GSK's Breo In COPD
Breo Ellipta is associated with a lower rate of exacerbations in real world Salford study, but some analysts question whether it's too late to turn performance around in a highly competitive, highly price-conscious market.
You may also be interested in...
Top-line data from a second patient group, asthmatics, in the Salford Lung Study indicate that switching from usual therapy to GSK’s’s Relvar Ellipta improves symptoms, but the results may not be enough to encourage switching before generic Seretide/Advair takes hold.
The firm's hands-off pragmatic trial in the UK paves the way for real world studies in other disease areas where there are many products and arguably little differentiation to sway payers on market access.
The UK pharma had pinned much of its long-term hopes for Breo on successful results of SUMMIT, which compared the morbidity and mortality of COPD patients at increased risk of cardiovascular disease taking Breo versus placebo.